Bacteria as trigger for chronic gastrointestinal disorders

Digestive Diseases

Volumn 29, Issue 2, 2011, Pages 166-171

  Marteau, Philippe ^a,b,c   Chaput, Ulriikka ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Bacteria; Bacteria induced adenocarcinoma; Bacteria induced lymphoma; Crohn's disease; Helicobacter pylori; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; IMIDAZOLE; MESALAZINE; METRONIDAZOLE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFAXIMIN;

BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIUM CULTURE; CAMPYLOBACTER ENTERITIS; CANCER RISK; CHRONIC DISEASE; COLORECTAL CANCER; CONFERENCE PAPER; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; ENTERITIS; ERADICATION THERAPY; FIRMICUTES; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; ILEITIS; IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE; NONHUMAN; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH LYMPHOMA; STREPTOCOCCUS; STREPTOCOCCUS BOVIS; STREPTOCOCCUS GALLOLYTICUS; ULCERATIVE COLITIS;

ANIMALS; BACTERIAL PHYSIOLOGICAL PHENOMENA; CHRONIC DISEASE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 79960143233     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000323879     Document Type: Conference Paper

References (42)

1. Doré J, Corthier G: The human intestinal microbiota. Gastroenterol Clin Biol 2010; 34(suppl 1):S7-S15.
2. Preidis GA, Versalovic J: Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009; 136: 2015-2031.
3. Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D: Whipple's disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 2008; 8: 179-190. (Pubitemid 351249251)
4. Cover TL, Blaser MJ: Helicobacter pylori in health and disease. Gastroenterology 2009; 136: 1863-1873.
5. Herrera V, Parsonnet J: Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect 2009; 15: 971-976.
6. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD: Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267-1271. (Pubitemid 24129959)
7. Sagaert X, Van Cutsem E, De Hertogh G, Geboes K, Tousseyn T: Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development. Nat Rev Gastroenterol Hepatol 2010; 7: 336-346.
8. Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdörffer E: Helicobacter heilmannii -associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118: 821-828. (Pubitemid 30243744)
9. Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, Bengoufa D, Feuillard J, Lavergne A, Gordon JI, Berche P, Guillevin L, Lortholary O: Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350: 239-248. (Pubitemid 38067636)
10. Newman JV, Kosaka T, Sheppard BJ, Fox JG, Schauer DB: Bacterial infection promotes colon tumorigenesis in Apc(Min/+) mice. J Infect Dis 2001; 184: 227-230. (Pubitemid 32614056)
11. Jordane B, Nguyen IS, Pini A, Gossé F, Richert S, Thiersé D, Van Dorsselaer A, Leize-Wagner E, Raul F, Klein JP, Schöller-Guinard M: Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S. bovis ). Carcinogenesis 2004; 25: 1477-1484. (Pubitemid 39162714)
12. Gupta A, Madani R, Mukhtar H: Streptococcus bovis endocarditis, a silent sign for colonic tumour. Colorectal Dis 2010; 12: 164-171.
13. Abdulamir AS, Hafidh RR, Mahdi LK, Aljeboori T, Abubaker F: Investigation into the controversial association of Streptococcus gallolyticus with colorectal cancer and adenoma. BMC Cancer 2009; 9: 403.
14. Schlegel L, Grimont F, Ageron E, Grimont PA, Bouvet A: Reappraisal of the taxonomy of the Streptococcus bovis/Streptococcus equinus complex and related species: description of Streptococcus gallolyticus subsp. gallolyticus subsp. nov., S. gallolyticus subsp. macedonicus subsp. nov. and S. gallolyticus subsp. pasteurianus subsp. nov. Int J Syst Evol Microbiol 2003; 53: 631-645. (Pubitemid 36675458)
15. Abdulamir AS, Hafidh RR, Bakar FA: Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammationdriven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol Cancer 2010; 9: 249.
16. Marteau P: Bacterial flora in inflammatory bowel disease. Dig Dis 2009; 27(suppl 1):99-103.
17. Rosenstiel P, Sina C, Franke A, Schreiber S: Towards a molecular risk map - recent advances on the etiology of inflammatory bowel disease. Semin Immunol 2009; 21: 334-345.
18. Wehkamp J, Stange EF: Is there a role for defensins in IBD? Inflamm Bowel Dis 2008; 14(suppl 2):S85-S87. Erratum in: Inflamm Bowel Dis 2009; 15: 1438-1447.
19. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, Glimcher LH: Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007; 131: 33-45. (Pubitemid 47505255)
20. Bentley RW, Keenan JI, Gearry RB, Kennedy MA, Barclay ML, Roberts RL: Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjects. Am J Gastroenterol 2008; 103: 1168-1172. (Pubitemid 351677966)
21. Kirkwood CD, Wagner J, Boniface K, Vaughan J, Michalski WP, Catto-Smith AG, Cameron DJ, Bishop RF: Mycobacterium avium subspecies paratuberculosis in children with early-onset Crohn's disease. Inflamm Bowel Dis 2009; 15: 1643-1655.
22. Sibartie S, Scully P, Keohane J, O'Neill S, O'Mahony J, O'Hanlon D, Kirwan WO, O'Mahony L, Shanahan F: Mycobacterium avium subsp. paratuberculosis (MAP) as a modifying factor in Crohn's disease. Inflamm Bowel Dis 2010; 16: 296-304.
23. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-421. (Pubitemid 39091889)
24. Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel JF, Darfeuille-Michaud A: CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007; 117: 1566-1574. (Pubitemid 46871341)
25. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, et al: Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52: 237-242. (Pubitemid 36115065)
26. Martinez C, Antolin M, Santos J, Torrejon A, Casellas F, Borruel N, Guarner F, Malagelada JR: Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol 2008; 103: 643-648. (Pubitemid 351405965)
27. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C, Chardon P, Marteau P, Roca J, Dore J: Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55: 205-211. (Pubitemid 43117279)
28. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez- Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736.
29. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43: 3380-3389. (Pubitemid 40981351)
30. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J: Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009; 15: 1183-1189.
31. Swidsinski A, Loening-Baucke V, Vaneechoutte M, Doerffel Y: Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm Bowel Dis 2008; 14: 147-161. (Pubitemid 351288036)
32. Rowan F, Docherty NG, Murphy M, Murphy B, Calvin Coffey J, O'Connell PR: Desulfovibrio bacterial species are increased in ulcerative colitis. Dis Colon Rectum 2010; 53: 1530-1536.
33. Preidis GA, Versalovic J: Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009; 136: 2015-2031.
34. Marteau P, Sokol H, Dray X, Seksik P: Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? Gastroenterol Clin Biol 2009; 33 (suppl 3):S228-S234.
35. Holubar SD, Cima RR, Sandborn WJ, Pardi DS: Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010; 6:CD001176.
36. Prantera C, Lochs H, Gionchetti P, Campieri M, Danese S, Fogli M, Scribano M, Grimaldi M: Rifaximin-EIR (extended intestinal release) 400 mg tablets in the treatment of moderately active Crohn's disease: results of the international, multicentre, randomised, double-blind, placebo-controlled trial RETIC (abstract). Gut 2010; 59(suppl 111)A1.
37. Rutgeerts P, Van Assche G, Vermeire S, D'Haens G, Baert F, Noman M, et al: Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856-861. (Pubitemid 40523538)
38. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623. (Pubitemid 39434105)
39. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.
40. Lakhdari O, Cultrone A, Tap J, Gloux K, Bernard F, Ehrlich SD, Lefèvre F, Doré J, Blottière HM: Functional metagenomics: a high throughput screening method to decipher microbiota-driven NF- κ B modulation in the human gut. PLoS One 2010; 5: 10.
41. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, Furet JP, Ugarte E, Muñoz-Tamayo R, Paslier DL, Nalin R, Dore J, Leclerc M: Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 2009; 11: 2574-2584.
42. Ehrlich DS, MetaHIT Consortium: Metagenomics of the intestinal microbiota: potential applications. Gastroenterol Clin Biol 2010; 34(suppl 1):S23-S28.